A Three-Part, Randomized, Double-Blind (Part A) and Open-Label (Part B and Part C), Multi-Dose, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3938577 in Healthy Participants and Participants with Type 1 Diabetes Mellitus
Latest Information Update: 13 May 2025
At a glance
- Drugs LY-3938577 (Primary) ; LY-3938577 (Primary) ; Insulin degludec; Insulin degludec
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eli Lilly and Company
Most Recent Events
- 06 May 2025 Planned End Date changed from 1 Aug 2025 to 1 Oct 2025.
- 06 May 2025 Planned primary completion date changed from 1 Aug 2025 to 1 Oct 2025.
- 24 Apr 2025 Planned End Date changed from 1 Jul 2025 to 1 Aug 2025.